All In Biotech

Drug Trial Radar · NCT07280832

Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors

Open-Label, Multicenter Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT108 Injection in Participants With Unresectable or Metastatic Melanoma and Urinary Tract Tumors

Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Dec 17, 2025

Primary completion

Nov 30, 2026

Study completion May 30, 2027

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Dec 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter Phase I/II clinical study conducted in participants with unresectable locally advanced or metastatic melanoma and urinary tract tumors, aiming to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of JMT108 Injection in this population. The study consists of Phase I and Phase II (including Phase IIa and Phase IIb), where Phase I is the dose-escalation stage, Phase IIa is the dose-expansion stage, and Phase IIb is the cohort-expansion stage.

Conditions

  • Unresectable Locally Advanced or Metastatic Melanoma
  • Unresectable Locally Advanced or Metastatic Urinary Tract Tumors

Interventions

  • JMT108Drug

    Intravenous (IV) administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicity (DLT) (Phase I)Time frame: Approximately 28 days.
  2. Adverse Events (AEs) (Phase I)Time frame: Through study completion, an average of 1 year
  3. Overall Response Rate (ORR) (Phase II)Time frame: To evaluate the efficacy of JMT108 in subjects.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • BeiJing Cancer Hospital EC

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.